Compositions useful as inhibitors of erk
CA 2369502 A1 · Owner: Xie, Xiaoling · Inventors: Xie, Xiaoling
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides a method of treating a disease state in mammals that is alleviated by treatment with a protein kinase inhibitor especially an ERK , inhibitor, which method comprises administering a compound having the pharmacophric features Grp1, Grp2 and Grp3: Grp 1 is an optionally substituted aryl or aliphatic group; Grp 2 is a heteroaromatic ring having one to three nitrogens, said ring comprising a hydrogen bond acceptor HBA2 optinally bonded to a hydrogen bond donor HBD2, and Grp3 is a heteroaromatic ring comprisng a hydrogen bond donor HBD1, with distances between the phrmacophoric features defined in the specification. The method is useful for treating cancer stroke, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 5, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 5, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 5, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.